IRIS
MASSARI, Francesco Saverio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 62
Continente sconosciuto - Info sul continente non disponibili 16
EU - Europa 14
AS - Asia 2
Totale 94
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 59
IT - Italia 13
BD - Bangladesh 2
CA - Canada 1
CR - Costa Rica 1
GB - Regno Unito 1
TT - Trinidad e Tobago 1
Totale 78
Salva come PNG Salva come JPEG
Città #
Council Bluffs 27
Milan 5
San Jose 5
Ashburn 4
Rome 4
Los Angeles 3
Santa Clara 3
Tampa 2
Albany 1
Atlanta 1
Barrie 1
Chaguanas 1
Concesio 1
Dallas 1
East Orange 1
Genoa 1
Heredia 1
Jacksonville 1
London 1
Naples 1
New York 1
Philadelphia 1
Rochester 1
Woodbridge 1
Totale 69
Salva come PNG Salva come JPEG
Nome #
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors 18
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 8
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 7
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 7
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 7
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 6
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) 6
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 6
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study 6
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial 4
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma 4
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 4
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 3
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies 3
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison 3
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 2
Totale 94
Salva come PNG Salva come JPEG
Categoria #
all - tutte 459
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 459
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20263 0 0 0 0 0 0 0 0 0 0 3 0
2026/202791 17 35 39 0 0 0 0 0 0 0 0 0
Totale 94